Medication
Women with bleeding disorders should avoid taking non-steroidal anti-inflammatory drugs for period pain, unless prescribed by a doctor with expertise in VWD (ie, Naprosyn/naproxen, ibuprofen, etc – these have many brand names; ask your local pharmacist to check for you).
Therapy
Substances
- Hemostatics
- Immunoglobulins, Intravenous
- Recombinant Proteins
- von Willebrand Factor
- recombinant FVIIa
- Factor VIIa
- Deamino Arginine Vasopressin
Nutrition
Von Willebrand disease is a serious condition that affects the blood and clotting ability of some dogs. Many dogs live a very normal life and owners don't even know their dog has a clotting problem until a blood draw, surgery, or injury occurs.
See more
The recent American Society of Hematology/ISTH/National Hemophilia Foundation/World Federation of Hemophilia 2021 guidelines on the diagnosis of von Willebrand disease (VWD) is an outstanding effort to unify the diagnosis of VWD. However, as mentioned in ...
Is Aleve safe to take with von Willebrand disease?
How do I treat the acquired von Willebrand syndrome?
Is it safe to von Willebrand?
What is the prognosis for von Willebrand disease?
Which blood component will be given to a patient with von Willebrand's disease?
In an emergency, doctors might give a person with VWD a blood product called cryoprecipitate to stop bleeding. It contains von Willebrand factor along with other factor proteins. However, since cryoprecipitate is not treated to kill viruses, it is not recommended.
Which of the following anticoagulant agents is used to treat von Willebrand's disease?
Approach Considerations. The main treatment options for patients with von Willebrand disease (vWD) are as follows : Desmopressin (DDAVP) - DDAVP is a synthetic analogue of the antidiuretic hormone vasopressin; it has enhanced antidiuretic activity and no pressor activity related to vasopressin.
How do you treat von Willebrand disease type 1?
Clinical experience indicates that FVIII level is the best predictor of soft tissue or surgical bleeding, whereas VWF:RCo normalization is required for an appropriate treatment of mucosal bleeding. Desmopressin and transfusion therapy with blood products represent the 2 treatments of choice in VWD41 (Figure 1).
What tube is used for von Willebrand disease?
Blood should be collected in a blue-top tube containing 3.2% buffered sodium citrate.
How does DDAVP work in von Willebrand's?
DDAVP causes the release of von Willebrand's antigen from the platelets and the cells that line the blood vessels where it is stored. Von Willebrand's antigen is the protein that carries factor VIII. This increase in von Willebrand's antigen and factor VIII helps to stop bleeding.
How does heparin work as an anticoagulant?
Heparin is a medication that inhibits clotting by activating your body's anti-clotting processes. One of the anticlotting processes uses a type of blood protein called antithrombin. Heparin works by activating antithrombin, and then antithrombin keeps other parts of the clotting process from working normally.
Which of the following is used in the treatment of hemophilia A?
Hemlibra® (also known as ACE 910 or emicizumab) It can be used to either prevent or reduce the frequency of bleeding episodes in people with hemophilia A. This treatment product can be given by injection under the skin.
What is von Willebrand factor antigen?
A von Willebrand factor (vWF) antigen test measures the quantity of a protein called von Willebrand factor that helps blood to clot. A clot is a lump of blood that the body produces to prevent excessive bleeding by sealing leaks in blood vessels caused by wounds, cuts, scratches, and other conditions.
How does desmopressin increase VWF?
Desmopressin exerts its haemostatic effect by:Inducing synthesis of the von Willebrand factor (VWF) by endothelial cells.Stimulating release of the VWF from its storage sites in endothelial cells.Cleaving the large VWF multimers circulating in plasma into smaller multimers.More items...
Which tube is most appropriate for a von Willebrand's test?
Blood should be collected in a blue-top tube containing 3.2% buffered sodium citrate.
What is included in a von Willebrand panel?
Von Willebrand factor testing includes VWF antigen, which measures the amount of VWF, and VWF activity (also known as Ristocetin Cofactor), which evaluates the function of VWF. Some laboratories may offer a panel that includes both of these tests along with a factor VIII activity test.
What is the test for von Willebrand disease?
Doctors order the vWF antigen test to help diagnose or monitor the treatment of von Willebrand disease. Often, doctors do this test along with others to get a fuller picture of clotting ability. These can include: clotting time tests such as prothrombin time [PT] and partial thromboplastin time [PTT]
What is von Willebrand disease?
Von Willebrand disease is a common autosomal inherited bleeding disorder caused by quantitative or qualitative defects of von Willebrand factor, a multi-adhesive protein that binds platelets to exposed subendothelium and carries factor VIII in circulation. As a result of von Willebrand factor deficiency or abnormality, levels of factor VIII, the protein deficient in hemophilia A, may be variably reduced. Clinical manifestations are mainly represented by mucous membrane and of soft tissue bleeding. Their severity is variable depending on the degree of von Willebrand factor and factor VIII reduction. While a clear-cut diagnosis is easy in severe von Willebrand factor reductions, the advantage of pursuing a definite diagnosis in mild or dubious cases should be weighed against the risk of over-medicalization. The aim of treatment is to correct the dual defect of hemostasis caused by the abnormal/reduced von Willebrand factor and the concomitant deficiency of factor VIII. Desmopressin is the treatment of choice for type 1 von Willebrand disease patients with factor VIII and von Willebrand factor levels of 10 U/dL or over who have proved responsive to a test-infusion with the compound. Von Willebrand factor/factor VIII concentrates are needed when desmopressin is ineffective (mainly type 2 and 3 von Willebrand disease).
How to diagnose VWD?
The diagnosis and appropriate classification of VWD usually requires an array of tests (Table 2) together with the evidence of a bleeding history, usually also present in other family members. The diagnosis should be undertaken in a specialized center for bleeding disorders that is capable of performing such assays accurately and providing the patients with a balanced view of their bleeding risk. When a diagnostic process is initiated, the physician should always take into consideration the practical advantage and the patient perspective of a specific diagnosis of VWD in any given patient, avoiding the risk of over-medicalization of patients with dubious or mild bleeding history.8A slightly reduced VWF level can be found even in normal subjects and bleeding symptoms are also frequently reported by ‘normal’ subjects.11–13For this reason, the patient should be interviewed about his/her bleeding history using a structured, written questionnaire to improve the quality of data collection and to reduce both intra- and inter-observer variability. Since in many cases the deficiency is mild and the risk of bleeding small, it is recommended that diagnosis be pursued especially in the presence of a significant bleeding history, obtained by using specifically designed questionnaires.13,14Collected data must be unambiguously interpreted to verify if the bleeding history is compatible with a bleeding disorder, and for this purpose a bleeding score (BS), accounting for both the number and the severity of the bleeding symptoms, may be useful. The BS is generated by summing the severity of all bleeding symptoms reported by a subject, and graded according to an a prioriscale.13,15Previous experience from the International Multicenter Study suggests that a bleeding score of 3 or over in males and of 5 or over in females could be considered as a useful cut off to identify adults with a bleeding diathesis in whom it is worth measuring VWF-related activities.13A novel questionnaire has been recently endorsed by the International Society on Thrombosis and Haemostasis (ISTH) to assess bleeding symptoms for the diagnosis of bleeding disorders.16
What is the first step in VWF testing?
The first step is to carry out a test with desmopressin. Candidates are those patients with basal FVIII and/or VWF:RCo below 30 U/dL. Patients with higher levels are very likely to respond and do not routinely require biological testing, although a test infusion may be useful in unraveling additional VWF abnormalities (e.g. shortened VWF half-life).
What is VWD based on?
The diagnosis of VWD is then based on the presence of reduced VWF:RCo (or VWF:CB) (<40 U/dL), with a further characterization of VWD type based on assessment of VWF:Ag, FVIII and multimer pattern. In general, VWF levels below 30 U/dL have been shown to be strongly associated with a significant clinical severity as assessed by a bleeding score17and the presence of mutations in the VWFgene.18However, levels under 40 U/dL and the presence of other relatives with equivalent levels are similarly a crucial clue for the diagnosis of mild VWD.14In these cases, bleeding history is milder and treatment usually rests on avoidance of anti-platelet drugs and antifibrinolytics as required.
What are the different types of VWD?
VWD is classified into three different types (Table 4).6Types 1 and 3 VWD reflect the partial or (virtually) complete quantitative deficiency of VWF, while type 2 VWD reflects qualitative defects of VWF. Type 1 is the most common form of VWD and is predominantly transmitted as an autosomal dominant trait often with incomplete penetrance (not all cases that inherit a VWF mutation demonstrate bleeding symptoms). Type 1 VWD is characterized by an equivalent mild to moderately severe reduction of VWF antigen (VWF:Ag) and ristocetin co-factor activity (VWF:RCo) in plasma. VWF multimers are essentially normal and certainly with a normal profile of high molecular weight forms, while plasma levels of FVIII are reduced, usually in proportion to VWF but often FVIII is higher than VWF. The severity of mucocutaneous bleeding symptoms usually correlates with the degree of their VWF and FVIII deficiencies. Type 2A is inherited mainly with an autosomal dominant pattern and the hallmark is represented by the lack of large and intermediate size VWF multimers. The laboratory hallmark of the most typical and frequent forms of type 2B is the heightened ristocetin induced platelet aggregation (RIPA) with mild to moderate thrombocytopenia and the absence of large multimers in plasma. In type 2M VWD the VWF multimer distribution is normal, but platelet-dependent VWF activities (VWF:RCo and/or von Willebrand factor collagen binding (VWF:CB)) are reduced. Type 2N is characterized by recessive inheritance, with mildly reduced or normal levels of VWF:Ag and VWF:RCo and a normal multimer pattern in most cases. Low plasma levels of FVIII (typically 5–40 U/dL) result from the decreased plasma half-life of FVIII, which cannot bind to VWF as a consequence of a qualitative abnormality of VWF. Type 3 VWD is inherited as an autosomal recessive trait and is characterized by undetectable levels of VWF (usually < 3 U/dL) and very low levels of FVIII (typically 1–5 U/dL), which may cause a more severe bleeding tendency characterized not only by mucocutaneous hemorrhages but also by hemarthroses and hematomas as in moderately severe hemophilia.
What is VWF/FVIII?
VWF/FVIII concentrates licensed for the treatment of von Willebrand disease in Europe.
What is the best treatment for a bleed in the mucosal tract?
Antifibrinolytic agents(i.e. tranexamic acid and epsilon aminocaproic acid), given orally, intravenously or topically, are useful alone or as adjuncts to replacement therapy (DDAVP or VWF/FVIII concentrates) for the prevention or treatment of bleeding in mucosal tracts, characterized by a high fibrinolytic activity.55Thus, they may be sufficient for the management of less severe forms of mucosal bleeding, epistaxis, menorrhagia or dental procedures and generally in mild VWF deficiencies. Furthermore, these agents are useful in association with replacement therapy during minor or major surgery involving mucosal surfaces. Tranexamic acid should be administered at a dose of 10–15 mg/kg 3–4 times a day, or more frequently if used as mouthwash for oral surgery or bleeding, and aminocaproic acid at a dose of 50–60 mg/kg every 4–6 h. These drugs are contraindicated in the management of urinary tract bleeding because of the risk of ureteral clots and hydronephrosis.
How to make sure von Willebrand disease does not interfere with enjoying a healthy life?
Receiving treatment when necessary and visiting your doctor regularly are the best ways to make sure von Willebrand disease does not interfere with enjoying a healthy life.
What is von Willebrand disease?
Von Willebrand disease (VWD) is a bleeding disorder in which your blood has trouble clotting. It is inherited, meaning it is passed down from parents to their children. People with von Willebrand disease sometimes experience heavier-than-normal bleeding from injury, surgery, and, in women, menstrual flow and childbirth.
What is VWF type 2?
Type 2: In this type, the VWF has a defect that makes it unable to work properly. Bleeding symptoms can be mild or moderate.
What is the name of the protein that causes von Willebrand disease?
Problems with a protein in the blood cause von Willebrand disease. This protein, known as von Willebrand factor (VWF), helps the blood clot.
Does von Willebrand disease have symptoms?
Many people with von Willebrand disease have mild cases and no symptoms. Symptoms in more severe cases include:
Is von Willebrand disease preventable?
Because von Willebrand disease is usually inherited, it is not preventable.
Can a mutation cause a reduced VWF?
In both of these scenarios the ability of the blood to clot properly is impaired. A variety of gene mutations cause either a reduced production of VWF or production of an abnormally functioning VWF. Although the cause of these mutations is unknown, the abnormal gene is passed from one generation to another.
What is the treatment for von Willebrand's disease?
There are two main options available for the management of von Willebrand's disease: desmopressin and transfusion therapy with blood products. Desmopressin is the treatment of choice in patients with Type 1 von Willebrand's disease, who account for approximately 80% of cases.
Is desmopressin effective in Type 3?
In Type 3 and in the majority of Type 2 patients, desmopressin is not effective and it is necessary to resort to plasma concentrates containing factor VIII and von Willebrand factor.
What is von Willebrand disease?
Related Pages. Von Willebrand disease (VWD) is a blood disorder in which the blood does not clot properly. Blood contains many proteins that help the blood clot when needed. One of these proteins is called von Willebrand factor (VWF). People with VWD either have a low level of VWF in their blood or the VWF protein doesn’t work the way it should.
What is VWD type 2?
Type 2. With this type of VWD, although the body makes normal amounts of the VWF, the factor does not work the way it should. Type 2 is further broken down into four subtypes―2A, 2B, 2M, and 2N―depending on the specific problem with the person’s VWF.
Who is Affected?
population. This means that 3.2 million (or about 1 in every 100) people in the United States have the disease. Although VWD occurs among men and women equally, women are more likely to notice the symptoms because of heavy or abnormal bleeding during their menstrual periods and after childbirth. There are 3 major types of VWD: Type 1, Type 2, and Type 3.
What happens when VWF is attached to platelets?
The body removes the platelets attached to VWF, causing a reduced amount of both platelets and VWF in the blood when needed to form a clot.
How does VWF work?
Normally, when a person is injured and starts to bleed, the VWF in the blood attaches to small blood cells called platelets. This helps the platelets stick together, like glue, to form a clot at the site of injury and stop the bleeding. When a person has VWD, because the VWF doesn’t work the way it should, the clot might take longer to form or form incorrectly and bleeding might take longer to stop. This can lead to heavy, hard-to-stop bleeding. Although rare, the bleeding can be serious enough to damage joints or internal organs, or even be life-threatening.
How long does VWD bleeding last?
This bleeding may be characterized in the following ways: After a cut to the skin, the bleeding lasts more than 5 minutes.
Why is VWF important?
Because the treatment is different for each type, it’s important that a person know which subtype he or she has. In Type 2A, the VWF is not the right size and doesn’t help the platelets attach together in order to form a clot. In Type 2B, the VWF attaches to platelets at the wrong time (when there is no injury).
What is the treatment for von Willebrand disease?
The main treatment options for patients with von Willebrand disease (vWD) are as follows [ 20] : Desmopressin (DDAVP) - DDAVP is a synthetic analogue of the antidiuretic hormone vasopressin; it has enhanced antidiuretic activity and no pressor activity related to vasopressin.
When was von Willebrand factor approved?
Recombinant von Willebrand factor (Vonvendi) was approved by the US Food and Drug Administration (FDA) in 2015. Approval was based on a phase 3 trial that showed that rVWF was safe and effective in treating 192 bleeds in 22 patients with vWD and stabilized endogenous FVIII:C levels. Control of bleeding was rated good or excellent, ...
How long does it take for a VWD 2A to respond to DDAVP?
Many individuals with vWD type 2A have a response to DDAVP, with peak vWF and FVIII levels at 30-60 minutes. This is similar to responses observed in patients with vWD type 1. However, rapid loss of vWF, FVIII, and particularly ristocetin cofactor ( RCoF) activity occurs as the high-molecular-weight multimers are degraded, with return to baseline levels at 4 hours post infusion. Although the response is transient, it may be adequate therapy in certain clinical situations.
What is DDAVP treatment?
DDAVP is the treatment of choice for individuals with vWD type I. The infusion of DDAVP into healthy individuals and individuals with vWD type 1 results in a rapid increase in circulating levels of vWF:Ag and FVIII and RCoF activity.
How long does it take for a vwf to stabilize?
Hemostatic levels are maintained until bleeding risk abates: usually 3 to 5 days for minor procedures and 7 to 14 days for major surgery.
How is DDAVP administered?
DDAVP can be administered not only through intravenous infusion but also via a highly concentrated nasal spray; 300 mcg intranasally produces levels comparable to those observed with an intravenous infusion. Intranasal treatment is particularly useful for home therapy of menorrhagia and recurrent epistaxis.
How many patients have type 3 alloantibody?
Alloantibody formation occurs in 10-15% of patients with type 3 disease. Therefore, the possibility of this complication must be managed appropriately, because patients are at increased risk for life-endangering anaphylactic reactions to vWF-FVIII preparations. With hemostatic stress in emergency situations, infusion of FVIII preparations devoid of vWF, while adjusting for the markedly decreased FVIII half-life, may be necessary.
Diagnosis
Clinical Trials
Lifestyle and Home Remedies
Preparing For Your Appointment
